

Colin Cooper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10615310/publications.pdf>

Version: 2024-02-01

17
papers

2,231
citations

516215

16
h-index

940134

16
g-index

17
all docs

17
docs citations

17
times ranked

5451
citing authors

#	ARTICLE	IF	CITATIONS
1	A urine-based DNA methylation assay, ProCURE, to identify clinically significant prostate cancer. <i>Clinical Epigenetics</i> , 2018, 10, 147.	1.8	26
2	Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer. <i>Scientific Reports</i> , 2017, 7, 5901.	1.6	49
3	New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 531-543.	1.1	24
4	The emerging role of FTY720 (Fingolimod) in cancer treatment. <i>Oncotarget</i> , 2016, 7, 23106-23127.	0.8	128
5	Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1 α and sphingosine kinase 1. <i>Oncotarget</i> , 2016, 7, 80943-80956.	0.8	32
6	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , 2015, 47, 736-745.	9.4	395
7	Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing. <i>Journal of Clinical Pathology</i> , 2015, 68, 212-217.	1.0	21
8	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. <i>Genome Research</i> , 2015, 25, 814-824.	2.4	69
9	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2014, 15, 1521-1532.	5.1	291
10	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , 2014, 345, 1251343.	6.0	348
11	Truncation of BRAF and Raf1 in prostate cancer in China.. <i>Journal of Clinical Oncology</i> , 2012, 30, 77-77.	0.8	0
12	PRKC- δ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention. <i>Genes and Cancer</i> , 2010, 1, 444-464.	0.6	46
13	Overexpression of RAD51 occurs in aggressive prostatic cancer. <i>Histopathology</i> , 2009, 55, 696-704.	1.6	85
14	Multiple loci on 8q24 associated with prostate cancer susceptibility. <i>Nature Genetics</i> , 2009, 41, 1058-1060.	9.4	273
15	Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. <i>Lancet Oncology</i> , The, 2008, 9, 342-351.	5.1	257
16	Amplification and Overexpression of the KIT Gene Is Associated with Progression in the Seminoma Subtype of Testicular Germ Cell Tumors of Adolescents and Adults. <i>Cancer Research</i> , 2005, 65, 8085-8089.	0.4	149
17	Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones. <i>Oncogene</i> , 2004, 23, 9142-9147.	2.6	38